Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.41 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.38 |
| ▸ | AVPR1A known ✓ | P37288 | 1/20 | 0.38 |
| ▸ | LRP6 | O75581 | 11/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | DKK1 | O94907 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19460949 | 0.99 | LRP6 (0.63) | LRP6CYP1A2CYP2C19HSD17B10DKK1 | |
| Hydrochloric Acid SCHEMBL29470937 | 0.88 | LRP6 (0.81) | LRP6CYP1A2CYP2C19HSD17B10DKK1 | |
| SCHEMBL22332092 | 0.67 | MEN1 (1.00) | CYP1A2CYP2C19HSD17B10HIF1AMEN1 | |
| SCHEMBL22062468 | 0.67 | MEN1 (1.00) | CYP1A2CYP2C19HSD17B10HIF1AMEN1 | |
| SCHEMBL19460827 | 0.64 | MEN1 (0.53) | CYP1A2CYP2C19HSD17B10CYP2D6HIF1A | |
| SCHEMBL11860823 | 0.64 | KMT2A (0.71) | CYP1A2CYP2C19HSD17B10MEN1MAPT | |
| SCHEMBL3226363 | 0.62 | S100B (0.56) | CYP1A2CYP2C19HSD17B10HIF1AMEN1 | |
| SCHEMBL17774966 | 0.62 | S100B (0.56) | CYP1A2CYP2C19HSD17B10MEN1MAPT | |
| SCHEMBL27572326 | 0.62 | MEN1 (0.52) | CYP1A2CYP2C19HSD17B10MEN1MAPT | |
| SCHEMBL13699678 | 0.61 | ALDH1A1 (0.53) | CYP1A2CYP2C19HSD17B10CYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419542-B1 | METHOD AND APPARATUS FOR TIGHTENING SKIN | MASSACHUSETTS GEN HOSPITAL (US) | 2025-05-14 | — | — | EP | claimed |
| US-20250143865-A1 | METHODS AND SYSTEMS FOR PREVENTING OR REDUCING STENOSIS IN A SUBJECT RECEIVING A GRAFT | MASSACHUSETTS GEN HOSPITAL (US) | 2025-05-08 | — | — | US | claimed |
| US-20250121118-A1 | SYSTEMS, APPARATUSES, KITS, AND METHODS FOR MODIFICATION OF TISSUE USING A PHOTO-INITIATOR AND LIGHT | DURVENA INC (US) | 2025-04-17 | — | — | US | claimed |
| US-12208001-B2 | Methods and systems for preventing or reducing stenosis in a subject receiving a graft | THE GENERAL HOSPITAL CORPORATION (US) | 2025-01-28 | — | — | US | claimed |
| US-20240377326-A1 | USE OF FLUORESCENT OR VISIBLE TRACERS TO MONITOR NUTRIENT CONCENTRATIONS IN SOLUTION | FEHR SOLUTIONS, LLC | 2024-11-14 | — | — | US | claimed |
| US-12019250-B2 | White dwarf: cross-polarized white light slide-free imaging | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-25 | — | — | US | claimed |
| US-20240149074-A1 | METHOD AND APPARATUS FOR TIGHTENING SKIN AND OTHER TISSUES | THE GENERAL HOSPITAL CORPORATION | 2024-05-09 | — | — | US | claimed |
| US-11883680-B2 | Method and apparatus for tightening skin and other tissues | THE GENERAL HOSPITAL CORPORATION (US) | 2024-01-30 | — | — | US | claimed |
| WO-2023043974-A1 | USE OF FLUORESCENT TRACERS TO MONITOR NUTRIENT CONCENTRATIONS IN SOLUTION | FEHR SOLUTIONS, LLC (US) | 2023-03-23 | — | — | WO | claimed |
| US-20220249221-A1 | METHODS FOR TISSUE PASSIVATION | THE GENERAL HOSPITAL CORPORATION (US) | 2022-08-11 | — | — | US | claimed |
| US-20220241607-A1 | METHOD AND APPARATUS FOR TIGHTENING SKIN AND OTHER TISSUES | GENERAL HOSPITAL CORPORATION, THE | 2022-08-04 | — | — | US | claimed |
| US-11400027-B2 | Kit and method for detecting porous dental hydroxyapatite | INCISIVE TECHNOLOGIES PTY LTD (AU) | 2022-08-02 | — | — | US | claimed |
| US-11400310-B2 | Method and apparatus for tightening skin and other tissues | THE GENERAL HOSPITAL CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| US-11337792-B2 | Methods for tissue passivation | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-24 | — | — | US | claimed |
| US-6472219-B1 | CONCENTRATION OF TREATMENT PRODUCTS APPLIED TO CUT FLOWER WATER, I.E. IN ORDER TO PREVENT LEAF YELLOWING, ETC. DETERMINED USING FLUOROESCENT INDICATOR | ONDEO NALCO COMPANY | 2002-10-29 | — | — | US | claimed |
| EP-4711042-A1 | TARGET OBJECT SEPARATION APPARATUS WITH IMPROVED QUALITY CONTROL, AND MANUFACTURING METHOD THEREOF | CURIOSIS INC. (KR) | 2026-03-18 | — | — | EP | disclosed |
| US-12578638-B2 | Photopolymer composition for hologram formation, hologram recording medium and optical elements | LG CHEM, LTD. (KR) | 2026-03-17 | — | — | US | disclosed |
| CN-1113075-A | Brittle oxide substrates strengthened by cross-linkable silanes | ATOCHEM NORTH AMERICA ELF (US) | 1995-12-06 | — | — | CN | disclosed |
| EP-0655953-A1 | BRITTLE OXIDE SUBSTRATES STRENGTHENED BY CROSS-LINKABLE SILANES | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995000259-A2 | BRITTLE OXIDE SUBSTRATES STRENGTHENED BY CROSS-LINKABLE SILANES | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12578638-B2 | Photopolymer composition for hologram formation, hologram recording medium and optical elements | PTK2B, PTK2, CYBA | GAA 4482/4885MAOB 405/4885GLA 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.